Pfizer/BioNTech booster vaccine reduces COVID-19 hospitalisations

International researchers have identified that the Pfizer/BioNTech booster vaccine is highly effective at reducing COVID-19 hospitalisations. Experts from the Clalit Research Institute and Harvard University have collaborated to investigate the efficacy of the Pfizer/BioNTech BNT162B2 booster vaccine against the Delta variant of SARS-CoV-2, discovering that it lowers hospitalisations from the disease. The study, based in Israel, utilised one of the world’s largest integrated health record databases, illuminating the effectiveness of a third “booster” dose of the BNT162B2 vaccine in a nationwide mass-vaccination setting. The investigation was partly funded by the recently announced Ivan and Francesca Berkowitz Family Living Laboratory.